Live Breaking News & Updates on Anita Afzali

Stay updated with breaking news from Anita afzali. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

No Adverse Effects From Steroids in Pregnant Women With EoE

Our recommendations about the use of steroids among this population are based on the safety data extrapolated mainly from pregnant women with asthma. ....

Virginia , United-states , Julton-tomanguillo-chumbe , Anita-afzali , American-college-of-gastroenterology , Virginia-university , University-of-cincinnati , Charleston-area-medical-center , Trinetx-global-collaborative-network , American-college , West-virginia-university , Pregnancy

Two Choices for Resection Defect Repair Show Similar Success

Two novel devices are similarly effective for tissue approximation of large endoscopic resection defects, but each has advantages. ....

Houston , Texas , United-states , Baylor-college-of-medicine , Boston , Massachusetts , Eli-lilly , Salmaana-jawaid , Anita-afzali , Bristol-myers-squibb-celgene , University-of-cincinnati , Boston-scientific

GALAXI 1: Continued subcutaneous Tremfya benefits IV induction non-responders with Crohn's

GALAXI 1: Continued subcutaneous Tremfya benefits IV induction non-responders with Crohn's
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Vancouver , British-columbia , Canada , British , Bykate-burba , Heather-biele , Anita-afzali , University-of-cincinnati-college-medicine , Cincinnati-college ,

Guselkumab Demonstrates Long-Term Benefit for Crohn Disease

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response. ....

Jan-wehkamp , Anita-afzali , Uc-health-anita-afzali , Johnson , University-of-cincinnati-college-medicine , Johnson-innovative-medicines , United-european-gastroenterology-week , Cincinnati-college , Johnson-innovative , Severely-active-crohn , Participants-with-moderately , Achieved-clinical-remission

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

Canada , Cincinnati , Ohio , United-states , Copenhagen , Køavn , Denmark , University-of-cincinnati , Japan , Spring-house , British-columbia , Americans